95%Confidence
1Views
FDASource
2026-04-12Date
Summary
The third Class II recall for Teva's Octreotide Acetate (30 mg) confirms widespread sterility assurance failures at Pharmathen International, severely impacting the entire product line. This pattern suggests deep-rooted quality system deficiencies that could lead to prolonged regulatory actions and loss of physician confidence in Teva's sterile products.
Actionable: Reduce positions in Teva until clarity emerges on the full scope of the manufacturing issues and FDA response.
AI Confidence: 95%
Data Points
firmTeva Pharmaceuticals USA, Inc
classificationClass II
statusOngoing
distributionNationwide in the USA
productOctreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30 mg, Single-dose 8 mL vial, Rx only, Manufactured in Greece BY: Pharmat
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now